Ampio pharmaceuticals announces top-line results from ap-013 phase iii study of ampion in adult patients suffering from severe osteoarthritis of the knee (oak)

Englewood, colo., sept. 15, 2021 /prnewswire/ --  ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced top-line results from ap-013, a randomized, saline-controlled, double-blind phase iii clinical study evaluating the efficacy of an intra-articular (ia) injection of ampion™ in adults with pain due to severe osteoarthritis of the knee (oak).
AMPE Ratings Summary
AMPE Quant Ranking